Anti-Obesity Drugs

Global Market Trajectory & Analytics

MCP-1722

EXECUTIVE ENGAGEMENTS

POOL

2273
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

409
Interactions with Platform & by Email

PARTICIPANTS

68
Unique # Participated

VALIDATIONS

22
Responses Validated*

COMPANIES

25
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

18

PAGES

73

EDITION

18

PRICE

USD 5450

CODE

MCP-1722


COMPETITIVE METRICS

COMPANY

D S N T

% *

98Fit

Login Required

A Better Weigh Center

Login Required

Aardvark Therapeutics

Login Required

Abbey Hospitals

Login Required

About Me

Login Required

Accomplish Health

Login Required

Actiphons

Login Required

Activate Brain and Body

Login Required

Adipo Therapeutic

Login Required

Adipogen International

Login Required

SUBMIT
* D = Dominant; S = Strong; N = Niche; T = Trivial
* Validated respondents are incentivized with cluster data
Note: Best viewed in Landscape Mode
VIEW ENTIRE POOL OF 25 COMPETITORS

Sign-in with email to View Deeper Validated Engagement Details -

  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Anti-Obesity Drugs estimated at US$1.5 Billion in the year 2020, is projected to reach a revised size of US$5.1 Billion by 2027, growing at a CAGR of 19.4% over the period 2020-2027.
The Anti-Obesity Drugs market in the U.S. is estimated at US$443.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$903.4 Million by the year 2027 trailing a CAGR of 19% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.2% and 16.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 13.5% CAGR.

SELECT PLAYERS

Eisai Co. Ltd. (Japan); F. Hoffmann-La Roche Ltd. (Switzerland); GlaxoSmithKline Plc; Novo Nordisk A/S (Denmark); Rhythm Pharmaceuticals (US); VIVUS Inc. (US)

SEGMENTS

» Segment (Anti-Obesity Drugs)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Obesity and Overweight Statistics
Recent Market Activity
Obesity - A Prelude
Anti-Obesity Drugs: A Market Characterized by High Unmet Needs
Currently Available Anti-Obesity Medications
Select Currently Available Short-term and Long-term Anti-Obesity Medication
Select Off-Label Drugs for Obesity
Saxenda Commands the AOM Market, Newer Drugs to Provide Impetus to Market Growth
Semaglutide: Highest Potential in the AOM Pipeline
Setbacks of Past Drugs
Positive Road Ahead for Belviq
Relaunch of Xenical
Relaunch of Contrave®
Reluctance among Patients, Physicians, and Payers Hurts Market Prospects
New Drug Development - High on the Agenda, Despite the Market Restraints
Anti-Obesity Drugs in Phase-III Clinical Trials: As of July 2018
Anti-Obesity Drugs in Phase-II Clinical Trials: As of July 2018
Anti-Obesity Drugs in Phase-I Clinical Trials: As of July 2018
Diabetes Drug Companies Attempt to Foray into the Anti-Obesity Drugs Space
Competitive Landscape
Novo Nordisk - The Leading Player in the Market
The United States - The Largest Obesity and Anti-Obesity Market
Europe - A Market with Vast Potential
Obesity Creeps Up in Developing Countries
2. FOCUS ON SELECT PLAYERS
F. Hoffmann-La Roche Ltd. (Switzerland)
GlaxoSmithKline Plc. (UK)
Eisai Co., Ltd. (Japan)
Novo Nordisk A/S (Denmark)
Rhythm Pharmaceuticals (USA)
VIVUS, Inc. (USA)
3. MARKET TRENDS & DRIVERS
Alarming Rise in Global Obesity Levels - The Major Growth Factor
Classification of BMI
Rising Incidence of Chronic Diseases Associated with Obesity Drive the Market Expansion
Growing Middle Class Population to Drive the Market Growth
Childhood Obesity - A Market with Unmet Needs
Commercial Weight-Loss Companies Foray into the Market
Online Drug Stores Boost Sales
Barriers to Development of Effective Drugs
Regulatory Additions - A Barrier to Entry?
High Drug Development Costs - A Major Setback
Weight Loss Alternatives - A Market Dampener
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Anti-Obesity Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
CANADA
Canada Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
JAPAN
Japan Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
CHINA
China Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
EUROPE
Europe Current & Future Analysis for Anti-Obesity Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
FRANCE
France Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
GERMANY
Germany Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
ITALY
Italy Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UNITED KINGDOM
UK Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
REST OF EUROPE
Rest of Europe Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
REST OF WORLD
Rest of World Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Total Companies Profiled: 25

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com